Compare Fulford India with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs GLENMARK PHARMA - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA GLENMARK PHARMA FULFORD INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 398.8 12.6 3,153.2% View Chart
P/BV x 6.2 1.8 343.8% View Chart
Dividend Yield % 0.1 0.5 15.8%  

Financials

 FULFORD INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
GLENMARK PHARMA
Mar-19
FULFORD INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs942712 132.4%   
Low Rs450484 93.1%   
Sales per share (Unadj.) Rs691.4349.6 197.7%  
Earnings per share (Unadj.) Rs11.532.8 35.0%  
Cash flow per share (Unadj.) Rs15.444.3 34.6%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.30.3 85.9%  
Book value per share (Unadj.) Rs380.0198.6 191.3%  
Shares outstanding (eoy) m3.90282.17 1.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.01.7 58.9%   
Avg P/E ratio x60.718.2 333.1%  
P/CF ratio (eoy) x45.313.5 336.2%  
Price / Book Value ratio x1.83.0 60.9%  
Dividend payout %17.46.1 286.0%   
Avg Mkt Cap Rs m2,714168,625 1.6%   
No. of employees `0000.412.0 3.7%   
Total wages/salary Rs m50520,561 2.5%   
Avg. sales/employee Rs Th6,073.08,196.0 74.1%   
Avg. wages/employee Rs Th1,137.41,708.1 66.6%   
Avg. net profit/employee Rs Th100.7768.5 13.1%   
INCOME DATA
Net Sales Rs m2,69698,655 2.7%  
Other income Rs m1252,081 6.0%   
Total revenues Rs m2,822100,736 2.8%   
Gross profit Rs m-4615,858 -0.3%  
Depreciation Rs m153,259 0.5%   
Interest Rs m103,346 0.3%   
Profit before tax Rs m5411,335 0.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m103,756 0.3%   
Profit after tax Rs m459,250 0.5%  
Gross profit margin %-1.716.1 -10.7%  
Effective tax rate %17.733.1 53.3%   
Net profit margin %1.79.4 17.7%  
BALANCE SHEET DATA
Current assets Rs m1,73866,968 2.6%   
Current liabilities Rs m54540,211 1.4%   
Net working cap to sales %44.327.1 163.2%  
Current ratio x3.21.7 191.6%  
Inventory Days Days4883 58.2%  
Debtors Days Days481 5.3%  
Net fixed assets Rs m1233,322 0.0%   
Share capital Rs m39282 13.8%   
"Free" reserves Rs m1,44355,770 2.6%   
Net worth Rs m1,48256,052 2.6%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m2,077132,888 1.6%  
Interest coverage x6.74.4 153.1%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.7 174.9%   
Return on assets %2.69.5 27.5%  
Return on equity %3.016.5 18.3%  
Return on capital %4.317.8 24.2%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1762,998 0.0%   
Fx outflow Rs m67322,859 2.9%   
Net fx Rs m-65640,140 -1.6%   
CASH FLOW
From Operations Rs m9013,242 0.7%  
From Investments Rs m105-6,990 -1.5%  
From Financial Activity Rs m-14-7,387 0.2%  
Net Cashflow Rs m181-2,971 -6.1%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 6.9 55.1%  
FIIs % 0.1 34.4 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 10.5 201.9%  
Shareholders   4,783 56,727 8.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  ALEMBIC LTD  ALKEM LABORATORIES  AJANTA PHARMA  

Compare FULFORD INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

WPI Inflation Data, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)

On Monday, Indian share markets witnessed negative trading activity throughout the day and ended lower.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS